DBI (diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) ) Blocking Peptide (the N terminal of DBI)(100ug)

This is a synthetic peptide designed for use in combination with anti-DBI Antibody (ARP32803_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Size

100ug

Reactivities

Hum

Format

Lyophilized powder

Presku

AAP32803

Target

DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-dependent adrenal steroidogenesis. Three pseudogenes located on chromosomes 6, 8 and 16 have been identified. Multiple transcript variants encoding different isoforms have been described for this gene.

Weight

12kDa

Gene Id

The peptide is characterized by mass spectroscopy

Alternative Names

ACBD1; ACBP; CCK-RP; EP; MGC70414